Accumulating data on these methylation markers including the six genes tested in this study (HOXD13, SFN, RASSF1a, P16, PCDHGB7, and hMLH1) is of interest for further evaluation as serum- or serum-based biomarkers for the detection and monitoring of breast cancer patients. This evidence concerns the gene HOXD13 and breast cancer.